Methotrexate Lederle 2,5 mg Tablets
PDF Leaflet Revision Date: 28 September 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers, severe psoriasis, and rheumatoid arthritis.
Dosage (summary)
Weekly doses of 10-25 mg for psoriasis and 2.5-20 mg for rheumatoid arthritis.
Onset of Action / Duration
Onset: 1-2 hours, Duration: 3-10 hours.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding due to risks of fetal harm.
Key Drug Interactions
- NSAIDs
- Leflunomide
- Probenecid
- Penicillins
- Sulphonamides
Contraindications
- Pregnancy
- Breastfeeding
- Severe liver disease
- Immunodeficiency
- Blood dyscrasias
Common side effects
- Ulcerative stomatitis
- Leukopenia
- Nausea
- Fatigue
- Diarrhea
Counselling Points
- Take weekly, not daily
- Discuss reproductive risks
- Monitor for signs of toxicity
- Avoid alcohol
Serious warnings
- Serious toxicity risk
- Potential for fatal infections
- Hepatotoxicity
- Bone marrow suppression
Important Disclaimer
The Methotrexate Lederle 2,5 mg Tablets professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
